2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

CEACAM5 antibody

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Fluorescent Dye

8

Inhibitory Antibodies

4

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P991060
    Cergutuzumab

    		Transmembrane Glycoprotein Cancer
    Cergutuzumab is a fully human IgG1 antibody that targets CEACAM5. The isotype control for Cergutuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
    Cergutuzumab
  • HY-P99054
    Tusamitamab

    		Transmembrane Glycoprotein ADC Antibody Cancer
    Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542) .
    Tusamitamab
  • HY-177434
    Precemtabart tocentecan

    Precem-TcT; M 9140

    		 Antibody-Drug Conjugates (ADCs) Transmembrane Glycoprotein Topoisomerase Cancer
    Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC .
    Precemtabart tocentecan
  • HY-P99542
    Tusamitamab ravtansine

    SAR-408701; HuMAb2-3-SPDB-DM4

    		 Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
    Tusamitamab ravtansine
  • HY-P99681
    Labetuzumab govitecan

    IMMU 130; hMN-14-SN-38

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer .
    Labetuzumab govitecan
  • HY-P990853
    Anti-CEACAM5 Antibody (4H11-8)

    		Transmembrane Glycoprotein Cancer
    Anti-CEACAM5 Antibody (4H11-8) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CEACAM5. Anti-CEACAM5 Antibody (4H11-8) reacts with human CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5). Anti-CEACAM5 Antibody (4H11-8) can be used for detecting CEACAM5 in cancer.
    Anti-CEACAM5 Antibody (4H11-8)
  • HY-P991469
    AMG-211

    MEDI-565

    		 Transmembrane Glycoprotein Cancer
    AMG-211 (MEDI-565) is a human monoclonal antibody (mAb) targeting CEACAM5/CEA/CD66e. AMG-211 can be used in Gastrointestinal cancer and Solid tumours research .
    AMG-211

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: